Your browser doesn't support javascript.
loading
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer, Lisa; Barlesi, Fabrice; Martinez-Garcia, Maria; Dieras, Veronique; Schellens, Jan H M; Spano, Jean-Philippe; Middleton, Mark R; Calvo, Emiliano; Paz-Ares, Luiz; Larkin, James; Pacey, Simon; Venturi, Miro; Kraeber-Bodéré, Françoise; Tessier, Jean J L; Eberhardt, Wilfried Ernst Erich; Paques, Michel; Guarin, Ernesto; Meresse, Valerie; Soria, Jean-Charles.
Affiliation
  • Zimmer L; Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany.
  • Barlesi F; Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Phase I unit, CIC- CPCET, Marseille, France.
  • Martinez-Garcia M; Department of Medical Oncology, Hospital del Mar and Cancer Research Program, IMIM, Barcelona, Spain.
  • Dieras V; Institute Curie, Paris, France.
  • Schellens JH; The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Spano JP; Hôpital La Pitié-Salpêtrière, IUC/UPMC, Paris, France.
  • Middleton MR; Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom.
  • Calvo E; START Madrid, Hospital Universitario Madrid Sanchinarro, Madrid, Spain.
  • Paz-Ares L; Hospital Virgen del Rocio, Seville, Spain.
  • Larkin J; Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Pacey S; University of Cambridge, Department of Oncology, Cambridge, United Kingdom.
  • Venturi M; Pharma Research and Early Development, Oncology, Roche Penzberg, Germany.
  • Kraeber-Bodéré F; Nuclear Medicine Department, Hôtel-Dieu University Hospital, Nantes, France.
  • Tessier JJ; Pharma Research and Early Development, Oncology, Roche, Switzerland.
  • Eberhardt WE; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Ruhrlandklinik, University Duisburg-Essen, Essen, Germany. wilfried.eberhardt@uni-duisburg-essen.de.
  • Paques M; Clinical Investigation Center 1423, Quinze-Vingts Hospital, Paris 6 University, Paris, France.
  • Guarin E; Pharma Research and Early Development, Oncology, Roche, Switzerland.
  • Meresse V; Pharma Research and Early Development, Oncology, Roche, Switzerland.
  • Soria JC; SITEP, Gustave Roussy Cancer Center, University Paris-Sud, Villejuif, Paris, France.
Clin Cancer Res ; 20(16): 4251-61, 2014 Aug 15.
Article in En | MEDLINE | ID: mdl-24947927
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazines / Benzamides / Proto-Oncogene Proteins / Ras Proteins / MAP Kinase Kinase Kinases / Proto-Oncogene Proteins B-raf / Mutation / Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazines / Benzamides / Proto-Oncogene Proteins / Ras Proteins / MAP Kinase Kinase Kinases / Proto-Oncogene Proteins B-raf / Mutation / Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: Germany